

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/923,070	08/06/2001	Hong Jin	7682-059-999	1768
20300	04/21/2003			
PENNIE AND EDMONDS			EXAMINER	
1155 AVENUE OF THE AMERICAS NEW YORK, NY 100362711			LUCAS, ZACHARIAH	
,			ART UNIT	PAPER NUMBER
			1648	13
			DATE MAILED: 04/21/2003	
			\int	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
·	1	JIN ET AL.				
Office Action Summary	09/923,070	Art Unit				
Office Action Summary	Examiner	1648				
	Zachariah Lucas					
Th MAILING DATE of this communication app ars on the cover sheet with the correspond nce address Period for Reply						
A SHORTENED STATUTORY PERIOD FO THE MAILING DATE OF THIS COMMUNIC - Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this commun - If the period for reply specified above is less than thirty (30) - If NO period for reply is specified above, the maximum statu - Failure to reply within the set or extended period for reply within the set or extended period f	CATION. F37 CFR 1.136(a). In no event, however, may a nication. days, a reply within the statutory minimum of this attory period will apply and will expire SIX (6) MO	reply be timely filed rty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) file	d on <u>04 April 2003</u> .					
•—	b)☐ This action is non-final.	·				
2) Since this application is in condition	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4) Claim(s) 25-37 is/are pending in the						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.	7) Claim(s) is/are objected to.					
8) Claim(s) <u>25-37</u> are subject to restricti	ion and/or election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed	I on is: a)∐ approved b)∐	disapproved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
 Certified copies of the priority documents have been received. 						
2. Certified copies of the priority	2. Certified copies of the priority documents have been received in Application No					
 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (P3) Information Disclosure Statement(s) (PTO-1449) P	PTO-948) 5) Notice	ew Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)				

Art Unit: 1648

m. . 1

DETAILED ACTION

- 1. This action is responsive to the amendment by the applicant filed on April 4, 2003 (the Response). In the action mailed on November 4, 2002, the Examiner required restriction among the inventions claimed by originally filed claims 1-24. In the Response, the Applicant cancelled all previously pending claims and added new claims to subject matter not originally claimed in the application. As these new claims comprise multiple inventions, as defined below, this action is a further restriction of the new claims necessitated by the amendment.
- 2. The reply filed on April 4, 2003 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): the applicant does not elect from each of the groups presented in the restriction requirement over the claims as filed. See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE** (1) **MONTH or**THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS

 TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

The applicant notes that the present claims do not fall within the restriction groups as described in the restriction requirement. However, this does not render the restriction moot.

Rather, this means that the newly presented claims and the election are non-responsive to the office action. See, 37 CFR 1.111, and MPEP § 714.19. As such, the applicant is required to elect, with or without traversal from one of the restriction groups presented in the prior action.

3. It is further noted that the newly elected claims are drawn to RSV virus comprising "a sequence heterologous to that of native RSV comprises at least one genetic modification

4 y . , 4

compared to the native RSV sequence." Such claims contradict themselves. The specification

defines a heterologous sequence as including genes of other viruses or pathogens (including

other RSV strains), cellular genes, or tumor antigens. Page 5, lines 30-37. Thus, the specification

clearly describes heterologous genes as being genes not native to the RSV being mutated.

Therefore, even if the applicant's claims were an appropriate response to the restriction

requirement, they would not enjoy written description support of the specification, and would be

indefinite as inherently contradictory.

Conclusion

4. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Zachariah Lucas whose telephone number is 703-308-4240. The

examiner can normally be reached on Monday-Friday, 8 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, James Housel can be reached on 703-308-4027. The fax phone numbers for the

organization where this application or proceeding is assigned are 703-308-4242 for regular

communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703-308-0196.

Un

April 16, 2003

Page 3